Answers are grounded in this paper and cite their sources.
Extramedullary failure is common during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. A history of extramedullary disease predicts an inferior response to blinatumomab therapy and a higher risk for relapse/progression at extramedullary sites. Most extramedullary failure cases retain CD19 expression.
No takes yet. Share an insight, caveat, or question.
Aldoss et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: